AWM
VRTX icon

AE Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

AE Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.92M Sell
3,871
-53
-1% -$23.5K 0.01% 673
2026
Q1 		$1.75M Buy
3,924
+1,194
+44% +$557K 0.01% 685
2025
Q4 		$1.24M Buy
2,730
+958
+54% +$413K 0.01% 741
2025
Q3 		$694K Sell
1,772
-696
-28% -$291K ﹤0.01% 855
2025
Q2 		$1.1M Buy
2,468
+1,304
+112% +$601K 0.01% 699
2025
Q1 		$564K Sell
1,164
-1
-0.1% -$466 ﹤0.01% 881
2024
Q4 		$469K Buy
1,165
+29
+3% +$13.4K ﹤0.01% 934
2024
Q3 		$528K Sell
1,136
-31
-3% -$14.9K ﹤0.01% 873
2024
Q2 		$547K Sell
1,167
-166
-12% -$72.1K 0.01% 859
2024
Q1 		$557K Sell
1,333
-21,275
-94% -$8.99M 0.01% 788
2023
Q4 		$9.73M Buy
22,608
+1,710
+8% +$632K 0.05% 402
2023
Q3 		$7.27M Buy
20,898
+4,351
+26% +$1.52M 0.04% 449
2023
Q2 		$5.82M Buy
16,547
+14,732
+812% +$4.96M 0.04% 494
2023
Q1 		$572K Sell
1,815
-3,181
-64% -$954K ﹤0.01% 1284
2022
Q4 		$1.44M Buy
4,996
+3,552
+246% +$1.08M 0.01% 857
2022
Q3 		$418K Buy
1,444
+227
+19% +$65.3K ﹤0.01% 1348
2022
Q2 		$343K Buy
1,217
+271
+29% +$72.5K ﹤0.01% 1380
2022
Q1 		$247K Buy
+946
New +$225K ﹤0.01% 1504
2021
Q3 		– Sell
-1,027
Closed -$207K – 1721
2021
Q2 		$207K Sell
1,027
-11,804
-92% -$2.47M ﹤0.01% 1494
2021
Q1 		$2.76M Buy
12,831
+11,782
+1,123% +$2.59M 0.03% 482
2020
Q4 		$248K Sell
1,049
-3,355
-76% -$770K ﹤0.01% 1205
2020
Q3 		$1.2M Buy
4,404
+2,111
+92% +$582K 0.02% 584
2020
Q2 		$666K Sell
2,293
-1,795
-44% -$487K 0.01% 755
2020
Q1 		$973K Buy
4,088
+2,324
+132% +$533K 0.02% 496
2019
Q4 		$386K Buy
+1,764
New +$357K 0.01% 818

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

AE Wealth Management's VRTX Position: Q2 2026 in Review

AE Wealth Management reduced its Vertex Pharmaceuticals (VRTX) stake by 1.4% in Q2 2026, selling an estimated $23.5K and leaving 3,871 shares worth $1.92M. The position accounts for 0.01% of the portfolio, ranked #673.

AE Wealth Management first reported a position in VRTX in Q4 2019 and has held it in 25 quarters since. The position peaked at $9.73M in Q4 2023. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • AE Wealth Management held 3,871 shares of Vertex Pharmaceuticals worth $1.92M as of Q2 2026.
  • AE Wealth Management sold 53 Vertex Pharmaceuticals shares in Q2 2026, an estimated $23.5K.
  • Vertex Pharmaceuticals made up 0.01% of AE Wealth Management's portfolio in Q2 2026, its #673 holding.
  • AE Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 25 quarters since.
  • AE Wealth Management's Vertex Pharmaceuticals position peaked at $9.73M in Q4 2023.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on AE Wealth Management's 13F filing for Q2 2026, filed 3 Aug 2026.